The Philadelphia Business Journal (Free subscription) | 10/28/2009
Morphotek Inc. entered into a license agreement Wednesday with Centocor Ortho Biotech Inc. covering the development and commercialization of an antibody that targets a specific antigen that is over-expressed in cancer patients with a variety of solid tumors. (JNJ)
Contract Pharma Breaking News (Free subscription) | 10/28/2009
Morphotek, Inc. has entered into a license agreement with Centocor Ortho Biotech for the development and commercialization of an antibody targeting solid tumors. Financial terms were not disclosed. Morphotek has been granted an exclusive worldwide license for the development, manufacture and sale of the antibody. Preclinical studies conducted by Centocor have shown that the relevant...
PR News Wire (Free subscription) | 10/28/2009
EXTON, Pa., Oct. 28 /PRNewswire/ -- Morphotek®, Inc., a subsidiary of Eisai Inc., announced today that it has entered into a license agreement with Centocor Ortho Biotech Inc. for development and commercialization of an antibody that targets a tumor-associated antigen over-expressed in many solid tumors.
Red Orbit (Free subscription) | 10/28/2009
EXTON, Pa., Oct. 28 /PRNewswire/ -- Morphotek®, Inc., a subsidiary of Eisai Inc., announced today that it has entered into a license agreement with Centocor Ortho Biotech Inc.
The Philadelphia Business Journal (Free subscription) | 09/25/2009
The Food and Drug Administration approved Centocor Ortho Biotech Inc.’s new drug application for its psoriasis drug Stelara.
Philadelphia Inquirer (Free subscription) | 11/04/2009
A company spokesman would not provide a current number for total employees in this region. Its Philadelphia area operations include McNeil Consumer & Specialty Pharmaceuticals in Fort Washington; Centocor Inc. in Horsham and Malvern; and pharmaceutical research and development in Spring House.
PR News Wire (Free subscription) | 11/02/2009
WALTHAM, Mass., Nov. 2 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, in the Crohn's disease drug market, the dominance of TNF-alpha inhibitors such as Abbott/Eisai's Humira and Centocor Ortho Biotech/Schering-Plough/Mitsubishi Tanabe's Remicade will continue over the next decade. Sales of Humira...
The Philadelphia Business Journal (Free subscription) | 11/03/2009
... has about 12,000 employees.Still unresolved following the merger is Merck’s rights to sales of Centocor’s arthritis medicine Remicade outside of the United States.Schering-Plough acquired those rights from Johnson & Johnson (NYSE:JNJ), which owns Centocor Ortho Biotech of Horsham, Pa. Johnson & Johnson is claiming the merger terminates the deal under a change-of-control provision...
PR News Wire (Free subscription) | 10/22/2009
... arthritis in the United States through 2011, but the more established branded drugs such as, Centocor Ortho Biotech's Remicade, Abbott's Humira and Amgen/Wyeth's Enbrel, in this class will face competition from newer entrants. The decline in use for these established drugs will stem from physicians increasing their use of UCB's Cimzia and Centocor Ortho Biotech's Simponi and prescribing...
PR News Wire (Free subscription) | 11/02/2009
... Officer, The World Bank Brian O'Donnell - Associate Director, Department of Medical Education, Centocor Ortho Biotech Inc. LLCAndrej Petroski - Director of Learning Technologies, Harrisburg UniversityMark Sharp - Vice President, Atlantic Link Global"We have found ourselves in trying times that have forced sales training departments, universities and every other kind of educational institution...
Medical News Today (Free subscription) | 10/23/2009
... of rheumatoid in the United States through 2011, but the more established branded drugs such as, Centocor Ortho Biotech's , Abbott's and Amgen/Wyeth's , in this class will face competition from newer entrants. The decline in use for these established drugs will stem from physicians increasing their use of UCB's and Centocor Ortho Biotech's Simponi and prescribing only one TNF-alpha...
The San Francisco Business Times (Free subscription) | 10/14/2009
Former executive Gail Maderis joined the board of privately held Trinity Biosystems.Trinity, of Menlo Park, is developing oral biotech drugs for endocrine and other disorders.Maderis was president and CEO of San Francisco's Five Prime from 2003 until stepping down in June. During that time, Five Prime inked deals with the likes of Pfizer Inc., Boehringer Ingelheim and Centocor Research and Development...
Philadelphia Inquirer (Free subscription) | 10/21/2009
Goldsmith, while positive about the newer biologics, cautioned against putting too much weight into a small study released at the conference this week by Finnish researchers. It suggested positive effects from a combination of methotrexate and the TNF infliximab - sold as Remicade by Horsham-based Centocor Ortho Biotech Inc.
iStockAnalyst.com (Free subscription) | 10/02/2009
In 1999, Wall Street analysts thought Johnson and Johnson had lost it... The health care conglomerate had a famously stodgy corporate culture. But that year, it dropped $4.9 billion to acquire a little-known antibody developer called Centocor. Johnson and Johnson paid 10.5 times sales – mighty pricey even during the 1999 market euphoria. But Johnson and Johnson knew exactly what kind of...
PR News Wire (Free subscription) | 09/29/2009
WALTHAM, Mass., Sept. 29 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, in addition to sales of Centocor Ortho Biotech/Schering-Plough/Mitsubishi Tanabe Pharma's Remicade, the two emerging TNF-alpha inhibitors Abbott/Eisai's Humira and Centocor Ortho Biotech/Schering-Plough/Mitsubishi Tanabe...
